Cargando…

Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer

Carbon nanotubes (CNTs), as advanced nanotechnology with specific properties and structures, have presented practical drug delivery properties. Ginsenoside Rg3 is a component of puffed ginseng and demonstrates anti-cancer activities. To explore the effect of CNTs-loaded Rg3 (Rg3-CNT) on the PD-1/PD-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Xiao, Wang, Hui, Ji, Degang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312428/ https://www.ncbi.nlm.nih.gov/pubmed/34111025 http://dx.doi.org/10.18632/aging.203131

Ejemplares similares

PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression
por: Alkaabi, Duaa, et al.
Publicado: (2023)

CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer
por: Shrestha, Mariusz, et al.
Publicado: (2023)

Effect of carbon nanotubes loading and pressure on the performance of a polyethersulfone (PES)/carbon nanotubes (CNT) membrane
por: Ngoma, Mlungisi Martin, et al.
Publicado: (2021)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer
por: Tashireva, Liubov A., et al.
Publicado: (2023)

Carbon Nanotube (CNT)-Based Biosensors
por: Ferrier, David C., et al.
Publicado: (2021)

Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
por: Ren, Yifan, et al.
Publicado: (2022)

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
por: Barrett, Michael T., et al.
Publicado: (2018)

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
por: Chen, Xingyu, et al.
Publicado: (2022)

NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer
por: Qin, Ge, et al.
Publicado: (2020)

Synthesis of Carbon Nanotube (CNT) Composite Membranes
por: Altalhi, Tariq, et al.
Publicado: (2010)

Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
por: Tang, Yuxia, et al.
Publicado: (2022)

A Meta-Analysis of Efficacy and Safety of PD-1/PD-L1 Inhibitors in Triple-Negative Breast Cancer
por: Wang, Chaoyang
Publicado: (2022)

Natural Blockers of PD-1/PD-L1 Interaction for the Immunotherapy of Triple-Negative Breast Cancer-Brain Metastasis
por: Nakhjavani, Maryam, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?
por: Mathias, Carolina, et al.
Publicado: (2023)

GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer
por: Cheng, Shun-Wen, et al.
Publicado: (2021)

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
por: Zaslavsky, Alexander B., et al.
Publicado: (2020)

The risk of PD-L1 expression misclassification in triple-negative breast cancer
por: Ben Dori, Shani, et al.
Publicado: (2022)

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2023)

Effects of Ginsenoside Rb(1) on Skin Changes
por: Kimura, Yoshiyuki, et al.
Publicado: (2012)

Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer
por: Qiu, Yufan, et al.
Publicado: (2021)

Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Yixi, et al.
Publicado: (2022)

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
por: Kumar, Sunny, et al.
Publicado: (2022)

Progress in the Conversion of Ginsenoside Rb1 into Minor Ginsenosides Using β-Glucosidases
por: Zhu, Hongrong, et al.
Publicado: (2023)

Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC)
por: Dobritoiu, Florin, et al.
Publicado: (2022)

Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines
por: Bräutigam, Karen, et al.
Publicado: (2021)

Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes
por: Nascimento, Catarina, et al.
Publicado: (2020)

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
por: Qi, Yihang, et al.
Publicado: (2022)

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis
por: Wu, Jinyao, et al.
Publicado: (2023)

PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis
por: Yu, Yinan, et al.
Publicado: (2023)

Theory of Carbon Nanotube (CNT)-Based Electron Field Emitters
por: Bocharov, Grigory S., et al.
Publicado: (2013)

RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer
por: Yang, Huijie, et al.
Publicado: (2022)

Antiobesity and Antihyperglycemic Effects of Ginsenoside Rb1 in Rats
por: Xiong, Ye, et al.
Publicado: (2010)

INHALATION EXPOSURE TO CARBON NANOTUBES (CNT) AND CARBON NANOFIBERS (CNF): METHODOLOGY AND DOSIMETRY
por: Oberdörster, Günter, et al.
Publicado: (2015)

Tumor Suppression by PD-1/PD-L1 Interaction Blockage in Mice Model
por: Salehi, Shima, et al.
Publicado: (2023)

Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
por: Sun, Woo Young, et al.
Publicado: (2016)

Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer
por: Shi, Shuai, et al.
Publicado: (2022)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development
por: Xiao, Xiyun, et al.
Publicado: (2022)

Ginseng extract and ginsenoside Rb1 attenuate carbon tetrachloride-induced liver fibrosis in rats
por: Hou, Ya-Ling, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5ni6nvqls9t93up90ah7d3qsri